Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
80 hedge funds and large institutions have $499M invested in Mirati Therapeutics, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
3% more funds holding
Funds holding: 78 → 80 (+2)
4% more capital invested
Capital invested by funds: $479M → $499M (+$20.7M)
100% less call options, than puts
Call options by funds: $5K | Put options by funds: $1.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$8.83M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.49M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.02M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.01M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$11.9M |
| 2 |
CCI
Columbus Circle Investors
|
-$10.5M |
| 3 |
O
OrbiMed
New York
|
-$7.34M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$6.89M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$4.3M |
MRTX Hedge Fund Activity: Q4 2015 in Review
80 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2015, worth a combined $499M — up 4.3% from $479M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new MRTX positions and 14 closed out — a net gain of 2 holders — while 34 added to existing stakes and 22 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $8.83M. The largest seller was Citigroup, cutting an estimated $11.9M.
- 80 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2015, up from 78 in Q3 2015.
- Funds reported $499M of Mirati Therapeutics, Inc. Common Stock stock for Q4 2015, up 4.3% quarter-over-quarter.
- 16 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2015 and 14 closed out, a net change of +2 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2015 was Ghost Tree Capital, an estimated $8.83M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2015 was Citigroup, an estimated $11.9M sold.
Based on aggregated 13F filings for Q4 2015.